Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) is now available.
Shanghai Haohai Biological Technology announced that controlling shareholder and de facto controller Jiang Wei has been released on bail by the Shanghai Municipal Public Security Bureau in connection with an ongoing insider trading investigation. The company emphasized that the case is unrelated to its operations and noted that Jiang holds no board, senior executive, or other official position within the firm.
The investigation follows an administrative penalty imposed on Jiang by the China Securities Regulatory Commission in late 2025 over insider trading activities. By reiterating that the matter pertains solely to a shareholder and not the listed entity, the company aims to reassure investors that its governance, daily operations, and regulatory status remain unaffected despite the heightened scrutiny around a major shareholder.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a PRC-incorporated biopharmaceutical company whose H-shares trade in Hong Kong and A-shares in Shanghai under the abbreviation HAOHAI BIOTEC. The company operates in the biomedical sector, focusing on biological technologies and related healthcare products for the domestic Chinese market and international investors.
Average Trading Volume: 163,754
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.64B
See more data about 6826 stock on TipRanks’ Stock Analysis page.